Technology areas: Biotechnology & Pharmaceuticals • Computing & Software • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Sumitomo Pharma Co., Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. Each matter is assigned to a distinct examiner and a distinct art unit, indicating that the active docket is distributed across separate examination assignments.
DANIEL, ANTARIUS S is the busiest examiner, with 1 pending matter. Counsel should therefore manage the matters individually while checking whether related pharmaceutical claim issues require a coordinated response strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DANIEL, ANTARIUS S | 1 | 52.0% | +14.4% |
| LEVERETT, MARY CHANG | 1 | 59.4% | +23.5% |
| BANERJEE, KOYELI | 1 | 33.3% | +0.0% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17794912 | DETERMINATION AGENT AND DETERMINATION METHOD FOR TAUOPATHY AND DEMENTIA-RELATED DISEASES | WANG, CHANG YU | 26d overdue |
| 18727500 | TISSUE TRANSPLANTATION RESIN TIP, TISSUE TRANSPLANTATION DEVICE, RETINA TISSUE TRANSPLANTATION METHOD, AND RETINA TISSUE TRANSPLANTATION KIT | DANIEL, ANTARIUS S | — |
| 18549967 | PREDICTION OF AMOUNT OF IN VIVO DOPAMINE ETC., AND APPLICATION THEREOF | LEVERETT, MARY CHANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17794912 | DETERMINATION AGENT AND DETERMINATION METHOD FOR TAUOPATHY AND DEMENTIA-RELATED DISEASES | WANG, CHANG YU | 26d overdue |
| 18727500 | TISSUE TRANSPLANTATION RESIN TIP, TISSUE TRANSPLANTATION DEVICE, RETINA TISSUE TRANSPLANTATION METHOD, AND RETINA TISSUE TRANSPLANTATION KIT | DANIEL, ANTARIUS S | — |
| 18549967 | PREDICTION OF AMOUNT OF IN VIVO DOPAMINE ETC., AND APPLICATION THEREOF | LEVERETT, MARY CHANG | — |
| Art Unit | Apps |
|---|---|
| 3783 | 1 |
| 2123 | 1 |
| 1658 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18727500 | TISSUE TRANSPLANTATION RESIN TIP, TISSUE TRANSPLANTATION DEVICE, RETINA TISSUE TRANSPLANTATION METHOD, AND RETINA TISSUE TRANSPLANTATION KIT | DANIEL, ANTARIUS S | 3783 | §103§112 | Non-Final OA | — | Pending | Jul 09, 2024 |
| 18549967 | PREDICTION OF AMOUNT OF IN VIVO DOPAMINE ETC., AND APPLICATION THEREOF | LEVERETT, MARY CHANG | 2123 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18217962 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | BANERJEE, KOYELI | 1658 | §103 | Final Rejection | — | Pending | Jul 03, 2023 |
| 17794912 | DETERMINATION AGENT AND DETERMINATION METHOD FOR TAUOPATHY AND DEMENTIA-RELATED DISEASES | WANG, CHANG YU | 1675 | §101§112 | Final Rejection | 26d overdue | Pending | Jul 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSumitomo Pharma Co., Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Antarius S Daniel has the most, with 1 of Sumitomo Pharma Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
